RecruitingPhase 3NCT07066280

Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer

Skin Repairing Cream for the Prevention of Radiation Dermatitis and Regulation of Skin Microbial Environment in Breast Cancer: A Multicenter, Prospective, Randomized Controlled Study


Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment

326 participants

Start Date

Apr 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Acute radiation dermatitis (ARD) is the most common treatment-related adverse reaction following radiotherapy after modified radical mastectomy and/or prosthetic breast reconstruction in breast cancer patients. Moderate-to-severe ARD may compromise cosmetic outcomes and quality of life, and even impair radiotherapy efficacy. Current pharmacological prophylactic measures clinically employed - including topical corticosteroids, superoxide dismutase, and trolamine cream - demonstrate suboptimal efficacy and lack high-level evidence-based medical support. Emerging research indicates an association between cutaneous microbial homeostasis and ARD development, suggesting that maintaining skin surface acidity and modulating microecological balance may represent more effective preventive strategies. This study evaluates the efficacy and safety of a natural weak-acid macromolecular/small molecular repair cream in preventing ARD among post-operative breast cancer patients receiving radiotherapy through skin microbiome modulation. We enrolled 326 high-risk early-stage breast cancer patients scheduled for post-operative radiotherapy and randomized them to compare the superiority of the natural weak-acid repair cream versus conventional care with moisturizer. Concurrent skin microbiome sampling was performed to assess microecological changes and their impact on ARD development. The findings will provide high-level clinical evidence and theoretical basis for the safer and more effective application of this natural weak-acid repair cream in preventing post-radiotherapy ARD in breast cancer patients.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a special skin repair cream can help prevent or reduce radiation-induced skin irritation (a common side effect of radiation therapy) in breast cancer patients who had a mastectomy and are receiving radiation treatment after surgery. **You may be eligible if...** - You are 18 to 69 years old - You have confirmed breast cancer and had a mastectomy (with or without reconstruction) - You are medically fit to receive radiation therapy - You have not received radiation therapy before - You are willing not to use other skincare products during the study **You may NOT be eligible if...** - You have previously had radiation therapy - You have serious conditions like heart, liver, or kidney disease, or immune system disorders like AIDS - You have an active skin condition or skin reactions from ongoing chemotherapy or immunotherapy - You are known to be allergic to the cream being tested - You are enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSkin Repairing Cream

Skin Repairing Cream containing natural weak-acid

OTHERCetaphil® Moisturizing Cream as Inactive Control

Cetaphil® Moisturizing Cream


Locations(1)

Sun Yat-sen Memorial Hospital

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07066280


Related Trials